Scientists unleash Triple-Threat immune attack on tough cancers
NCT ID NCT03388632
Summary
This early-stage study tested a new combination of three immune-boosting drugs (IL-15, nivolumab, and ipilimumab) in adults with advanced cancers that had stopped responding to standard treatments. The main goal was to find the safest dose and understand the side effects of using these powerful drugs together. Researchers also looked for early signs that the treatment could help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.